NASDAQ:ROIV - Roivant Sciences Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $12.33
  • Forecasted Upside: 166.38 %
  • Number of Analysts: 8
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 8 Buy Ratings
  • 0 Strong Buy Ratings
$4.63
▲ +0.21 (4.75%)

This chart shows the closing price for ROIV by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Roivant Sciences Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ROIV and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ROIV

Analyst Price Target is $12.33
▲ +166.38% Upside Potential
This price target is based on 8 analysts offering 12 month price targets for Roivant Sciences in the last 3 months. The average price target is $12.33, with a high forecast of $0.00 and a low forecast of $0.00. The average price target represents a 166.38% upside from the last price of $4.63.

This chart shows the closing price for ROIV for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 8 polled investment analysts is to buy stock in Roivant Sciences.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/10/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/10/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/9/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/7/2021
  • 0 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/5/2022
  • 0 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/5/2022
  • 0 strong buy ratings
  • 8 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/4/2022
  • 0 strong buy ratings
  • 8 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/4/2022

Latest Recommendations

  • 0 strong buy ratings
  • 8 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
6/30/2022HC WainwrightReiterated RatingBuy$14.00Low
6/29/2022SVB LeerinkBoost Price TargetOutperform$6.00 ➝ $7.00Low
5/24/2022The Goldman Sachs GroupLower Price TargetBuy$15.00 ➝ $12.00High
5/23/2022SVB LeerinkInitiated CoverageOutperform$6.00High
4/29/2022Cantor FitzgeraldInitiated CoverageOverweight$15.00High
12/15/2021The Goldman Sachs GroupInitiated CoverageBuy$15.00High
12/5/2021SVB LeerinkReiterated RatingBuyN/A
11/8/2021HC WainwrightInitiated CoverageBuy$14.00Low
11/1/2021SVB LeerinkInitiated CoverageOutperform$11.00Low
10/27/2021CitigroupInitiated CoverageBuy$11.00High
10/26/2021Truist FinancialInitiated CoverageBuy$15.00High
10/26/2021Jefferies Financial GroupInitiated CoverageBuy$10.00High
10/26/2021CowenInitiated CoverageOutperformHigh
(Data available from 7/5/2017 forward)

News Sentiment Rating

0.62 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 2 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
12/7/2021
  • 1 very positive mentions
  • 11 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
1/6/2022
  • 0 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
2/5/2022
  • 2 very positive mentions
  • 0 positive mentions
  • 3 negative mentions
  • 3 very negative mentions
3/7/2022
  • 1 very positive mentions
  • 3 positive mentions
  • 1 negative mentions
  • 2 very negative mentions
4/6/2022
  • 0 very positive mentions
  • 3 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
5/6/2022
  • 1 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/5/2022
  • 7 very positive mentions
  • 16 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/5/2022

Current Sentiment

  • 7 very positive mentions
  • 16 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Roivant Sciences logo
Roivant Sciences Ltd., a biopharmaceutical and healthcare technology company that researches and develops medicines. The company develops product candidates for the treatment of various therapeutics, including solid tumors, sickle cell diseases, hypophosphatasia, oncologic malignancies, psoriasis, atopic dermatitis, vitiligo, hyperhidrosis, acne, myasthenia gravis, warm autoimmune hemolytic anemia, thyroid eye diseases, sarcoidosis, and staph aureus bacteremia. The company was founded in 2014 and is based in London, the United Kingdom.
Read More

Today's Range

Now: $4.63
Low: $4.19
High: $4.72

50 Day Range

MA: $3.95
Low: $2.81
High: $4.79

52 Week Range

Now: $4.63
Low: $2.52
High: $16.76

Volume

56,913 shs

Average Volume

1,013,168 shs

Market Capitalization

$3.20 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.58

Frequently Asked Questions

What sell-side analysts currently cover shares of Roivant Sciences?

The following sell-side analysts have issued research reports on Roivant Sciences in the last twelve months: Cantor Fitzgerald, Citigroup Inc., Cowen Inc, HC Wainwright, Jefferies Financial Group Inc., SVB Leerink LLC, The Goldman Sachs Group, Inc., and Truist Financial Co..
View the latest analyst ratings for ROIV.

What is the current price target for Roivant Sciences?

0 Wall Street analysts have set twelve-month price targets for Roivant Sciences in the last year. Their average twelve-month price target is $12.33, suggesting a possible upside of 166.4%.
View the latest price targets for ROIV.

What is the current consensus analyst rating for Roivant Sciences?

Roivant Sciences currently has 8 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe ROIV will outperform the market and that investors should add to their positions of Roivant Sciences.
View the latest ratings for ROIV.

How do I contact Roivant Sciences' investor relations team?

Roivant Sciences' physical mailing address is Clarendon House, 2 Church Street, Hamilton Parish HM 11. The company's listed phone number is 44 4412 955 950. The official website for Roivant Sciences is roivant.com. Learn More about contacing Roivant Sciences investor relations.